HSBC vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HSBC presents a contradictory profile, anchored by a weak Piotroski F-Score of 2/9 which indicates significant fundamental health concerns. While the stock shows explosive YoY revenue and earnings growth, this is offset by a poor earnings track record with an average surprise of -52.96% and a bearish technical trend (10/100). There is a massive valuation gap between the Graham Number ($41.8) and the growth-based Intrinsic Value ($177.0), suggesting the current price of $89.96 is speculative. Despite these risks, the dividend profile remains stable and the forward P/E is attractive.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
HSBC vs JPM: Head-to-Head Comparison
This page compares HSBC Holdings plc (HSBC) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.